eFFECTOR Therapeutics, Inc.
EFTR Healthcare Biotechnology
Follow EFTR
eFFECTOR Therapeutics, Inc. (EFTR) EV/Sales
As of 15 October 2026, eFFECTOR Therapeutics, Inc. (EFTR) trades at a EV/Sales of 3.2×. Over the past ten years it has ranged from 0.0× (September 2021) to 68.3× (March 2022); the current reading is higher than 48% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | 7.7× | (83.30%) |
| FY2022 | 46.4× | (1.28%) |
| FY2021 | 47.0× | — |
| FY2020 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2022 | 7.7× | (1.36%) |
| Sep 2022 | 7.9× | (50.94%) |
| Jun 2022 | 16.0× | (65.94%) |
| Dec 2021 | 47.0× | 563.07% |
| 4 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR compare | −2.8× |
| SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR compare | n/m |
| VRPX Virpax Pharmaceuticals, Inc. compare | n/m |
| CDT CDT Equity Inc. compare | n/m |
| VINC Vincerx Pharma, Inc. compare | n/m |
| ATXI Avenue Therapeutics, Inc. compare | n/m |
| CERO CERo Therapeutics Holdings, Inc. compare | n/m |
| SEELQ Seelos Therapeutics, Inc. compare | 0.5× |
| EFTR eFFECTOR Therapeutics, Inc. | 3.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)